Artiva (ARTV) has filed for a proposed IPO.
The company describes itself as: “We are a clinical-stage biotechnology company focused on developing natural killer cell (NK)-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic ) instead of a patient’s own cells (autologous) and are pre-manufactured, stored frozen and ready to be shipped to a patient’s treatment site, making them, in our opinion, ‘off-the-shelf’. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B cell-targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN). an investigator-initiated trial (IIT) in multiple autoimmune indications Major, peer-reviewed clinical trials of autologous CD19 chimeric antigen receptor (CAR) T cell therapy (auto-CAR-T) for the treatment of autoimmune diseases have shown that deep exhaustion. of B cells in the periphery and in lymphoid tissue can lead to remission of the disease without drugs. We have already shown that AlloNK in combination with rituximab was able to induce deep depletion of B cells in the periphery and observe complete responses in severe disease. pretreated patients naïve to auto-CAR-T in our ongoing Phase 1/2 clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). We believe the preliminary results of our Phase 1/2 A clinical trial evaluating AlloNK in combination with rituximab in patients with B-NHL provides insight into autoimmune diseases as efficacy in both diseases appears to be achieved with a shared mechanism of action which is accompanied by depletion of B cells in the periphery and in lymphoid tissues, followed by an immunological reset and reconstitution of B cells. We expect to report initial data on autoimmune indications from at least one of our phase 1/1b studies or the basket IIT in the first half of 2025.”
Jefferies, TD Cowen and Cantor will act as lead underwriters.
